Silence Therapeutics plc (SLNCF) Financial Statements (2026 and earlier)

Company Profile

Business Address 12 HAMMERSMITH GROVE
LONDON, W6 7AP
State of Incorp.
Fiscal Year End December 31
Industry (SIC) 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete Financial Analysis Financial Benchmarking

Balance Sheet (Statement of Financial Position) ($ in thousands)

3/31/2026
MRQ
12/31/2025
12/31/2024
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments, including:85,100147,300
Cash and cash equivalent11,277121,330
Short-term investments73,83726,004
Other undisclosed cash, cash equivalents, and short-term investments(14)(34)
Receivables 2,607972
Other current assets11,53714,664
Other undisclosed current assets19,41424,430
Total current assets:118,658187,366
Noncurrent Assets
Operating lease, right-of-use asset167157
Property, plant, and equipment, after accumulated depreciation, depletion, and amortization1,5811,818
Intangible asset, including goodwill, after accumulated amortization10,9099,704
Goodwill10,6219,392
Intangible asset, excluding goodwill, after accumulated amortization288312
Other noncurrent assets1273,590
Total noncurrent assets:12,78415,269
TOTAL ASSETS:131,442202,635
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities13,35616,399
Accounts payable13,35616,399
Deferred revenue 168306
Other undisclosed current liabilities89117
Total current liabilities:13,61316,822
Noncurrent Liabilities
Liabilities, other than long-term debt55,52551,790
Deferred revenue55,45451,790
Operating lease, liability71 
Total noncurrent liabilities:55,52551,790
Total liabilities:69,13868,612
Equity
Equity, attributable to parent62,304134,023
Common stock10,29010,288
Additional paid in capital617,562609,560
Accumulated other comprehensive loss(2,976)(11,781)
Accumulated deficit(562,572)(474,044)
Total equity:62,304134,023
TOTAL LIABILITIES AND EQUITY:131,442202,635

Income Statement (P&L) ($ in thousands)

3/31/2026
TTM
12/31/2025
12/31/2024
Revenues3,48043,258
Other income3,4804,472
Cost of revenue
(Cost of Product and Service Sold)
(215)(11,810)
Other undisclosed gross profit(2,921) 
Gross profit:34431,448
Operating expenses(91,421)(94,767)
Operating loss:(91,077)(63,319)
Nonoperating income (expense)(4,987)5,118
Gain (loss), foreign currency transaction, before tax(8,467)646
Other nonoperating income3,4804,472
Loss from continuing operations before equity method investments, income taxes:(96,064)(58,201)
Other undisclosed income from continuing operations before income taxes7,46313,737
Loss from continuing operations before income taxes:(88,601)(44,464)
Income tax expense(11)(845)
Net loss available to common stockholders, diluted:(88,612)(45,309)

Comprehensive Income ($ in thousands)

3/31/2026
TTM
12/31/2025
12/31/2024
Net loss:(88,612)(45,309)
Other comprehensive income (loss)8,804(1,055)
Comprehensive loss, net of tax, attributable to parent:(79,808)(46,364)

Statements Sources

The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: